HIRmAb-GDNF does not induce improve parkinsonian signs and is associated with type I hypersensitivity reaction.
figureposted on 20.02.2013, 03:45 by Sachiko Ohshima-Hosoyama, Heather A. Simmons, Nichole Goecks, Valerie Joers, Christine R. Swanson, Viktoriya Bondarenko, Rebecca Velotta, Kevin Brunner, Laura D. Wood, Ralph H. Hruban, Marina E. Emborg
(A) Clinical rating score. (B) Fine motor skills task. (C) Hypersensitivity response over time, by treatment group. (D) Optical density (OD) of HIRmAb-GDNF antibody levels in serum.